LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Magnetic resonance spectroscopy as a decision tool in multimodality treatment design for localised prostate cancer

    Giuseppe Sasso / Aleksandra Zapotoczna / David Pryor / John Simpson

    Oncology Reviews, Vol 3, Iss

    2011  Volume 4

    Abstract: Predicting the outcome of individual prostate adenocarcinoma can be challenging, especially for patients affected by intermediate or high risk, but localised disease. Natural histories of prostate cancers with similar stage and prognostic factors can ... ...

    Abstract Predicting the outcome of individual prostate adenocarcinoma can be challenging, especially for patients affected by intermediate or high risk, but localised disease. Natural histories of prostate cancers with similar stage and prognostic factors can differ significantly; and an ongoing debate surrounds the optimal treatment choice for men diagnosed with non-metastatic prostate cancer. A variety of effective therapeutic options are available to be used as a sole modality, or in combination, including surgery, external beam radiotherapy, brachytherapy, and endocrine manipulation. Although these treatments have been used routinely for more than 15 years, there is a paucity of data from randomised trials comparing their results. In addition, most treatment techniques have changed dramatically in the last two decades due to the ongoing healthcare technological revolution. The rapid proliferation of new and expensive therapeutic options (i.e. adaptive radiotherapy, focal ablation, etc.) promises to minimise treatment related side effects and improve local control, however, there is no uniform consensus. Treatment choice is based on the available prognostic factors and life expectancy, along with patient preference, toxicity profiles, the individual institution’s (and clinician’s) experience and resource availability. Unfortunately, our prognostic tools are still limited, as is our ability to precisely predict which subset of patients might benefit from more aggressive therapeutic combinations. Therefore, a significant number of patients receive unnecessary and expensive treatments, whilst others are denied highly technological procedures because of associated resource limitation. This paper aims to analyse the current evidence, cost-effectiveness and controversies, surrounding the nonsurgical treatment of localised prostate cancer, with a focus on radiation and endocrine therapies, and to discuss the role of magnetic resonance spectroscopy, as a decision tool for multimodality treatment design and prediction of ...
    Keywords Cost-effectiveness - Magnetic resonance spectroscopy - Prostate cancer - Multimodality treatment ; Other systems of medicine ; RZ201-999 ; Internal medicine ; RC31-1245
    Subject code 610
    Language English
    Publishing date 2011-12-01T00:00:00Z
    Publisher PAGEPress Publications
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer.

    Zapotoczna, Aleksandra / Sasso, Giuseppe / Simpson, John / Roach, Mack

    Neoplasia (New York, N.Y.)

    2007  Volume 9, Issue 6, Page(s) 455–463

    Abstract: Prostatic neoplasms are not uniformly distributed within the prostate volume. With recent developments in three-dimensional intensity-modulated and image-guided radiation therapy, it is possible to treat different volumes within the prostate to different ...

    Abstract Prostatic neoplasms are not uniformly distributed within the prostate volume. With recent developments in three-dimensional intensity-modulated and image-guided radiation therapy, it is possible to treat different volumes within the prostate to different thresholds of doses. This approach has the potential to adapt the dose to the biologic aggressiveness of various clusters of tumor cells within the gland. The definition of tumor burden volume in prostate cancer can be facilitated by the use of magnetic resonance spectroscopy (MRS). The increasing sensitivity and specificity of MRS to the prostate is causing new interest in its potential role in the definition of target subvolumes at higher risk of failure following radical radiotherapy. Prostate MRS might also play a role as a noninvasive predictive factor for tumor response and treatment outcome. We review the use of MRS in radiation therapy for prostate cancer by evaluating its accuracy in the classification of aggressive cancer regions and target definition; its current role in the radiotherapy planning process, with special interest in technical issues behind the successful inclusion of MRS in clinical use; and available early experiences as a prognostic tool.
    MeSH term(s) Brachytherapy/methods ; Humans ; Magnetic Resonance Spectroscopy ; Male ; Prostatic Neoplasms/radiotherapy ; Radiation Oncology ; Radiotherapy Dosage
    Language English
    Publishing date 2007-07-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1483840-0
    ISSN 1476-5586 ; 1522-8002
    ISSN (online) 1476-5586
    ISSN 1522-8002
    DOI 10.1593/neo.07277
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Current Role and Future Perspectives of Magnetic Resonance Spectroscopy in Radiation Oncology for Prostate Cancer

    Aleksandra Zapotoczna / Giuseppe Sasso / John Simpson / Mack Roach, III

    Neoplasia : An International Journal for Oncology Research, Vol 9, Iss 6, Pp 455-

    2007  Volume 463

    Abstract: Prostatic neoplasms are not uniformly distributed within the prostate volume. With recent developments in three-dimensional intensity-modulated and imageguided radiation therapy, it is possible to treat different volumes within the prostate to different ... ...

    Abstract Prostatic neoplasms are not uniformly distributed within the prostate volume. With recent developments in three-dimensional intensity-modulated and imageguided radiation therapy, it is possible to treat different volumes within the prostate to different thresholds of doses. This approach has the potential to adapt the dose to the biologic aggressiveness of various clusters of tumor cells within the gland. The definition of tumor burden volume in prostate cancer can be facilitated by the use of magnetic resonance spectroscopy (MRS). The increasing sensitivity and specificity of MRS to the prostate is causing new interest in its potential role in the definition of target subvolumes at higher risk of failure following radical radiotherapy. Prostate MRS might also play a role as a noninvasive predictive factor for tumor response and treatment outcome. We review the use of MRS in radiation therapy for prostate cancer by evaluating its accuracy in the classification of aggressive cancer regions and target definition; its current role in the radiotherapy planning process, with special interest in technical issues behind the successful inclusion of MRS in clinical use; and available early experiences as a prognostic tool.
    Keywords Magnetic resonance spectroscopy ; prostatic neoplasms ; radiotherapy ; biological imaging ; chemical shift imaging ; Medicine ; R ; Internal medicine ; RC31-1245 ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282
    Subject code 290
    Publishing date 2007-06-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top